Cancer antigen 19-9 (CA19-9), also known as the carbohydrate antigen Sialyl-Lewis(a) (sLe(a)), is widely expressed on epithelial tumors of the gastrointestinal tract and breast and small-cell lung cancer. Overexpression of sLe(a) appears to be a key event in invasion and metastasis of many tumors, and CA19-9 is elevated in most patients with advanced pancreatic cancer. Still, it may also be elevated in other cancers and diseases such as bowel cancer, lung cancer, gall bladder cancer, gall stones, pancreatitis, cystic fibrosis, and liver disease. CA19-9 is used to diagnose and monitor pancreatic cancer progression, and high levels are associated with a poor prognosis. CA19-9 assays are based on the two-site sandwich ELISA or CLIA assay principle.

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

Learn More

Welcome to

Please select your country to continue